Vasomera

Vasomera, developed by PhaseBio Pharmacetuicals Inc., is a long-acting analogue of vasoactive intestinal peptide (VIP). It has been used as an adjunctive therapy for treatment and prevention of cardiomyopathy and Duchenne Muscular Dystrophy, among others. Preclinical studies show vasomera allows for early diastolic relaxation, peripheral vasorelaxation, and reduction of inflammation and fibrosis. In June, 2020, PhaseBio Pharmaceuticals began a randomized, double-blind, parallel group study to explore vasomera efficacy in improving clinical outcomes of COVID-19 patients at high risk for ARDS and death (NCT04433546).